Parabilis Medicines enters Nasdaq after an upsized IPO with a rare mix of platform ambition, heavyweight private investors, Regeneron validation and a first-in-class oncology lead program. The opportunity is real, but so are the risks: early-stage clinical proof, no commercial revenue, post-IPO valuation pressure, and the challenge of turning a hard-to-drug biology platform into approved medicines.

Three biotech financing headlines crossed the market within the same short window: IDEAYA Biosciences (Nasdaq: $IDYA) priced a roughly $300 million public offering, Shattuck Labs (Nasdaq: $STTK) priced a roughly $75 million public offering, and Eloxx Pharmaceuticals (Nasdaq: $ELOX) announced a roughly $66 million public offering alongside an uplisting to the Nasdaq Capital Market.

V012 Phase 3 interim readout expected on June 11, 2026
Humacyte has said that top-line interim results from the Phase 3 V012 study in hemodialysis vascular access are expected to be available for reporting on June 11, 2026 at the SVS Vascular Annual Meeting in Boston. If the data are supportive, the company expects to pursue a supplemental BLA submission in the second half of 2026 for the AV access indication in hemodialysis patients.

Citius Oncology has moved beyond the old “approved asset waiting for launch” phase. LYMPHIR is now on the U.S. market, revenue has started, and payer/formulary access appears to be building. The same story, however, still carries serious small-cap biotech risks: dilution, limited runway, Nasdaq bid-price pressure, manufacturing transition, and extreme price volatility.

All-cash deal at $124 per share — 40% premium to prior close. GSK’s largest oncology acquisition in over a decade. Two NDAs under FDA review, one PDUFA in September 202

BCDA BioCardia deep dive — CardiAMP cell therapy, FDA PMA path confirmed June 2026, Japan PMDA Q4 2026. Educational content only.

A full trader-focused deep dive on Nurix Therapeutics, the Roche collaboration for bexobrutideg, the company’s targeted protein degradation platform, its clinical and partnered pipeline, financial runway, ownership profile, catalysts, risks and the scenarios that matter after the June 8 announcement.

After OCS-01 failed to meet the primary visual acuity endpoint in both DIAMOND Phase 3 trials for diabetic macular edema, Oculis is no longer a clean near-term DME filing story. The new setup is a cash-rich ophthalmology and neuro-ophthalmology pipeline reset, with Privosegtor and Licaminlimab now carrying the next real tests.

Primary endp

Fulcrum was previously framed on Merlintrader as a cleaner but harsher one-asset biotech setup: pociredir had shown real fetal hemoglobin movement, but the next value bridge depended on FDA alignment, trial design and long-term safety confidence. The June 2026 update did not merely delay that bridge. It broke it.